Monitor FDA feedback in Q2 2026—clearance could catalyze positive momentum. The stock may react to trial initiation or interim data in Q4 2026. Watch for dilutive financing, as early-stage biotechs like QNTM often raise capital ahead of clinical milestones.
Price Chart
Executive Summary
Quantum BioPharma (QNTM) announced the submission of an Investigational New Drug (IND) application to the FDA for Lucid-21-302 (Lucid-MS), a first-in-class therapy targeting demyelination in multiple sclerosis. Subject to FDA clearance, the company plans to initiate a Phase 2 trial in Q2 2026, marking a key clinical advancement for this early-stage biotech. The press release emphasizes strategic positioning in a $38B+ MS market but contains no financial results or revenue figures.
Key Facts
- Submitted IND application to the FDA for Lucid-MS, a first-in-class candidate for multiple sclerosis.
- Phase 2 trial planned for Q2 2026, pending FDA clearance; interim data expected Q4 2026.
- Lucid-MS targets demyelination directly, differentiating it from most immune-modulating MS therapies.
- Company retains 19.84% stake in Unbuzzd Wellness Inc. and receives 7% royalty on sales until $250M paid, then 3% in perpetuity.
- No financial metrics (revenue, EPS, cash flow) disclosed in the release.
Financial Impact
No immediate financial impact; potential long-term value from clinical progression and royalty stream.
Risk Factors
- FDA may not clear the IND, delaying or halting development.
- High risk typical of early-stage biotech: Phase 2 failure would likely severely impact share price.
- Market cap ($28M) reflects high expectations; any setback could trigger sharp downside.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3266579 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 18d ago | 6-K | $3.11 | awaiting T+20 | — | $2.21 (−28.94%) |
Oct 6, 2026 21d ago | 6-K | $3.09 | awaiting T+20 | — | $2.21 (−28.48%) |
Oct 6, 2026 21d ago | Press Release | $3.09 | awaiting T+20 | — | $2.21 (−28.48%) |
Oct 5, 2026 21d ago | SC 13G/A | $3.27 | awaiting T+20 | — | $2.21 (−32.42%) |
Sep 24, 2026 4w ago | 6-K | $4.00 $2.27 | ▼ −43.25% | ▼ −42.83% | $2.21 (−44.75%) |
Sep 17, 2026 5w ago | 6-K | $3.72 $2.71 | ▼ −27.15% | ▼ −28.36% | $2.21 (−40.59%) |
Sep 17, 2026 5w ago | 6-K | $3.72 $2.71 | ▼ −27.15% | ▼ −28.36% | $2.21 (−40.59%) |
Sep 15, 2026 5w ago | 6-K | $3.46 $2.89 | ▼ −16.47% | ▼ −19.45% | $2.21 (−36.13%) |
Sep 1, 2026 7w ago | 6-K | $3.08 $3.60 | ▲ +16.88% | ▲ +17.21% | $2.21 (−28.25%) |
Sep 1, 2026 7w ago | Press Release | $3.08 $3.60 | ▲ +16.88% | ▲ +17.21% | $2.21 (−28.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers